NCT05016778: Phase 1: (OriCAR-017) - CAR-T Cells Targeting GPRC5D in the Treatment of RRMM - POLARIS

(OriCAR-017)

CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS)

NCT05016778: Phase 1: A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard treatments.

Sponsor:

Zhejiang University

Collaborator:

Oricell Therapeutics Co., Ltd

Location:

China, Zhejiang

The first affiliated hospital of medical college of zhejiang university

Hangzhou, Zhejiang, China, 310003

---

ClinicalTrials.gov Identifier: NCT05016778

Official Title: A Single Arm, Open Label Clinical Study of CAR-T Cells Targeting GPRC5D in the Treatment of Relapsed / Refractory Multiple Myeloma (POLARIS)

First Posted: August 23, 2021

Click here to see details on ClinicalTrials.gov

---

Drug: GPRC5D-CAR-T